Minocycline-induced cutaneous pigmentation is an adverse effect that may be more common than is generally realized. It is usually reported in patients undergoing chronic minocycline therapy for acne vulgaris.
Objective:
The case of a 69-year-old woman taking minocycline for rheumatoid arthritis is presented, and its differential diagnosis discussed in order to characterize the clinical features of minocycline-induced cutaneous pigmentation.
Conclusion:
Patients undergoing minocycline therapy for rheumatoid arthritis may develop bluish-grey pigmentation over the legs and forearms.
Get full access to this article
View all access options for this article.
References
1.
TilleyBCAlarconGSHeyseSP. Minocycline in rheumatoid arthritis: A 48-week, double-blind, placebo-controlled trial. MIRA Group. Ann Intern Med1995; 122:81–89.
2.
HeldJLSilversDNGrossmanME. Hyperpigmentation of the lower extremities associated with porphyria cutanea tarda. Arch Dermatol1989; 125:297–298.
3.
GransteinRDSoberAJ. Drug- and heavy metal-induced hyperpigmentation. J Am Acad Dermatol1981; 5:1–18.
4.
StanoveA. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA1965; 191:263–268.
5.
LevantineAAlmeydaJ. Drug-induced changes in pigmentation. Br J Dermatol1973; 89:105–112.
6.
TuffanelliDAbrahamRKDuboisEI. Pigmentation from antimalarial therapy: Its possible relation to the ocular lesions. Arch Dermatol1963; 88:419–426.
7.
KleinADPardoRJGouldE. Blue-gray discoloration of the face. Arch Dermatol1989; 125:417.
8.
AlinoviAReverberiCMelissariM. Cutaneous hyperpigmentation induced by amiodarone hydrochloride. J Am Acad Dermatol1985; 12:563–566.
9.
MahlerRSissonsWWattersK. Pigmentation induced by quinidine therapy. Arch Dermatol1986; 122:1062–1064.
10.
HashimotoKJoselowSATyeMJ. Imipramine hyperpigmentation: A slate-gray discoloration caused by long-term imipramine administration. J Am Acad Dermatol1991; 25:357–361.
HoshawRAZimmermanKGMenterA. Ochronosis-like pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol1985; 121:105–108.
13.
LittJZ. Drug eruption reference manual, 1998. New York: Parthenon Publishing, 1998:157–158, 429.
14.
BorkK. Cutaneous side effects of drugs. Philadelphia, PA: WB Saunders, 1988:201.
15.
KnowlesSRShapiroLShearNH. Serious adverse reactions induced by minocycline: Report of 13 patients and review of the literature. Arch Dermatol1996; 132:934–939.
16.
GouldenVGlassDCunliffeWJ. Safety of long-term high-dose minocycline in treatment of acne. Br J Dermatol1996; 134:693–695.
17.
ThibaultM-JBillickRCSrolovitzH. Minocycline-induced Sweet's syndrome. J Am Acad Dermatol1992; 27:801–804.
18.
SillerGMTodMASavageNW. Minocycline-induced oral pigmentation. J Am Acad Dermatol1994; 30:350–354.
19.
KatzJBarakSShemerJ. Black tongue associated with minocycline therapy. Arch Dermatol1995; 131:620–621.
20.
Parniex-SpakeABastuji-GarinSLobutJ-B. Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol1995; 131:490–491.
21.
KarofskyPS. Minocycline-induced rash in an 18-year-old patient. Arch Pediatr Adolesc Med1995; 149:217–218.
22.
BridgesAJGrazianoFMCalhounW. Hyperpigmentation, neutrophilic alveolitis, and erythema nodosum resulting from minocycline. J Am Acad Dermatol1990; 22:959–962.
23.
ChuPVanSLYenTSB. Minocycline hyperpigmentation localized to the lips: An unusual fixed drug eruption?J Am Acad Dermatol1994; 30:802–803.
24.
DwyerCMCuddihyAMKerrREI. Skin pigmentation due to minocycline treatment of facial dermatoses. Br J Dermatol1993; 129:158–162.
25.
ArgenyiZBFinelliLBergfeldWF. Minocycline-related cutaneous hyperpigmentation as demonstrated by light microscopy and x-ray energy spectroscopy. J Cutan Pathol1987; 14:176.
FenskeNMillnsJLGreerKE. Minocycline-induced pigmentation at sites of cutaneous inflammation. JAMA1980; 244: 1103–1106.
28.
BaslerRSWKohnenPW. Localized hemosiderosis as a sequelae of acne. Arch Dermatol1978; 114:1695–1697.
29.
LeverWF. Histopathology of the skin. Lippincott, 1996:294.
30.
AltmanDAFivensonDPLeeMW. Minocycline hyperpigmentation: A model for in situ phagocytic activity of factor XIIIa-positive dermal dendrocytes. J Cutan Pathol1992; 19:340.
31.
RidgwayHASonnexTSKennedyCTC. Hyperpigmentation associated with oral minocycline. Br J Dermatol1982; 107:95–102.
32.
SatoSMurphyGFBernhardJD. Ultrastructural and x-ray microanalytical observations of minocycline-related hyperpigmentation of the skin. J Invest Dermatol1981; 77:264–271.
33.
PepineMFlowersFPRamos-CaroFA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol1993; 28:292–295.
34.
CaroI. Discoloration of the teeth related to minocycline therapy for acne. J Am Acad Dermatol1980; 3:317–318.
35.
BaslerRSW. Minocycline therapy for acne. Arch Dermatol1979; 115:1391–1392.
36.
WolfeIDReichmisterJ. Minocycline hyperpigmentation: Skin, tooth, nail, and bone involvement. Cutis1984; 33:457–458.
37.
WhiteSWBesanceneyC. Systemic pigmentation from tetracycline and minocycline therapy. Arch Dermatol1983; 119:1–2.
